John L. Bishop
Chairman and Chief Executive Officer
Mr. Bishop joined Cepheid as Chief Executive Officer and as a director in April 2002, and became Chairman of the Board of Directors in February 2013. From 1993 to 2002, Mr. Bishop served as President, later President and Chief Executive Officer, and a director of Vysis, Inc., a genomic disease management company that was acquired by Abbott. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. Prior to that, from 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. Before joining Gen-Probe, Mr. Bishop held various management positions between 1968 and 1984 at American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation. Mr. Bishop served as a director of Conceptus from February 2009 until June 2013 when it was acquired by the Bayer Group. He has been a member of the AdvaMed Dx Board, since 2010, and was elected Chairman in December 2013. In 2011, Mr. Bishop received the Ernst & Young Entrepreneur Of The Year® Northern California Award in the Life Sciences category.
Executive Vice President, Global Human Resources
Mr. Fitzgerald joined us as our Senior Vice President, Global Human Resources in 2012. Prior to joining us, Mr. Fitzgerald was Senior Vice President of Human Resources at Verigy, Ltd (now a part of Advantest Corporation). Before Verigy, Mr. Fitzgerald was Vice President of Human Resources for Varian, Inc. (acquired by Agilent Technologies) and earlier was the Global Director, Human Resources Strategy and Planning for Vodafone Group, PLC. Mr. Fitzgerald brings more than two decades of broad Human Resources experience to Cepheid. He earned a bachelor’s degree in Political Science at the University of California, Berkeley, and a master’s degree in Industrial Relations and Personnel Management at the University of London’s London School of Economics and Political Science. Mr. Fitzgerald is currently a participant in the International Masters in Practicing Management (IMPM) program under of the auspices of McGill University of Montreal, Canada.
Kerry Flom, Ph.D.
Executive Vice President & Chief Regulatory Officer
Dr. Flom was promoted to Senior Vice President, Clinical Affairs and Regulatory Submissions in January 2010 and became our Executive Vice President, Chief Regulatory Officer in January 2013. From May 2004 to January 2010, Dr. Flom served as our Vice President, Clinical Affairs and Regulatory Submissions. Prior to joining Cepheid, Dr. Flom was Senior Director, Clinical Affairs and Regulatory Submission for Abbott Molecular Diagnostics from 2001 to 2004. Prior to Abbott, Dr Flom directed the clinical affairs departments at Vysis, Inc., Baxter Health Corporation – Cardiovascular Group (presently Edwards Lifesciences), and Oncor, Inc. Before joining Oncor, Dr. Flom has held clinical and R&D positions at Boehringer Mannheim Corporation (presently Roche Diagnostics), Behring Diagnostics, and Corning, Corporation.
Executive Vice President of International Commercial Operations
Philippe Jacon joined Cepheid as Executive Vice President of International Commercial Operations in January 2013, responsible for the international growth strategy of the company, encompassing both commercial sales and the HBDC program. Prior to Cepheid, Mr. Jacon was CEO of the Foundation for Innovative New Diagnostics (FIND) and Director General ad interim of the European Diagnostic Manufacturers Association (EDMA). Before joining EDMA in March of 2011, Mr. Jacon held a number of positions of increasing responsibility with Becton Dickinson (BD), most recently as Worldwide President of BD Diagnostics, Diagnostic Systems and Worldwide President of BD Diagnostics, Microbiology Systems. Other roles during his 23 years at BD included Vice President and General Manager for BD Medical, Diabetes Care in Europe and Vice President and General Manager for BD Medical, Pharmaceutical Systems in the United States. Mr. Jacon started his career at BD as a Sales Representative in France for BD Biosciences. He holds a degree in Microbiology from the Université de Bretagne Occidentale in France.
Executive Vice President, Global Operations
Mr. Kocmond joined us as Executive Vice President, Global Operations in May of 2013. Prior to joining Cepheid, Mr. Kocmond served as Vice President of Global Operations for Lam Research Corporation,where he was responsible for globally dispersed operations, including a multi-billion dollar supply chain. Prior to Lam Research, Mr. Kocmond was Executive Vice President of Global Operations and Quality at Verigy, Ltd., now a wholly owned subsidiary of Advantest Corp. Mr. Kocmond previously held operations and management positions at Applied Materials and Silicon Graphics, among other companies, and brings well over two decades of relevant experience to the Company.
Andrew D. Miller
Executive Vice President, Chief Financial Officer
Mr. Miller first joined us as our Senior Vice President, Chief Financial Officer in April 2008, and became our Executive Vice President, Chief Financial Officer in January 2012. Prior to joining Cepheid, Mr. Miller was Vice President of Finance and Chief Accounting Officer for Autodesk, an enterprise software company, from March 2005 to April 2008 and Vice President of Finance and Corporate Controller from May 2003 to March 2005. At Autodesk, he was responsible for global accounting and compliance operations. Before joining Autodesk, from 2000 to 2003, Mr. Miller was Senior Vice President and Chief Financial Officer for MarketFirst Software, Inc., a leading provider of enterprise marketing automation software. Prior to MarketFirst, Mr. Miller served as Vice President of Worldwide Finance for Cadence Design Systems, Vice President of Finance and Corporate Controller for Adaptive Broadband Corporation, and senior financial roles for Silicon Graphics, Inc. Mr. Miller started his career as an auditor with Deloitte, where he became a Certified Public Accountant, and he also serves on the Santa Clara University Leavey School of Business Advisory Board.
David H. Persing, M.D., Ph.D.
Executive Vice President, Chief Medical & Technology Officer
Dr. Persing first joined us as a director in May 2004, and became our Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was Senior Vice President and Chief Scientific Officer at Corixa Corporation, a Seattle-based biotechnology company, until its acquisition by GlaxoSmithKline. Prior to that he was a member of the Clinical and Research Faculty in the Department Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, Minnesota where he developed several extramurally funded research programs in infectious diseases. From 1992 to 1999 he established and directed the Mayo Molecular Microbiology Laboratory was one of the first reference laboratories to offer cutting-edge molecular diagnostic testing on a worldwide basis. He has authored over 270 peer-reviewed articles including frequently cited papers in the New England Journal of Medicine, Science, PNAS. He served as Editor in Chief for four leading textbooks on Molecular Diagnostics, the most recent of which was released in January 2011. Dr. Persing received his MD and PhD (Genetics) degrees from the University of California, San Francisco in 1988 and completed his clinical pathology residency training at the Yale School of Medicine in 1990.
Executive Vice President, North America Commercial Operations
Mr. Post joined us in December 2013 from Alere, Inc., where he most recently served as Global President of Acute Care with overall responsibility for global sales of multiple hundreds of millions of dollars. In this capacity, he was also responsible for sales and marketing in North America, in addition to product development, marketing and finance for the global hospital business. In total, Mr. Post spent ten years at Alere and its predecessor companies Inverness Medical and Biosite. Prior to Alere, Mr. Post spent approximately ten years at the United States Surgical Corporation in a variety of sales and marketing positions, including Vice President of Sales.
Joseph H. Smith
Executive Vice President, Corporate Development and General Counsel
Mr. Smith joined us in June 2003 as Vice President, General Counsel and has served as our Senior Vice President of Business Development and General Counsel since April 2004. He has been Secretary of the Corporation since March 2004. From 1989 to 2002, Mr. Smith was Vice President of Intellectual Property at Applied Biosystems (now Life Technologies Corporation) and its predecessors, a biotechnology research equipment company, and from 2002 to 2003 was its Senior Vice President for Business Development. Prior to Applied Biosystems, Mr. Smith was a partner in the law firm of Wiseman, Jones, and Smith; and prior to that he was a member of the Technical Legal Department of Hewlett-Packard.
President, Cepheid HBDC
Paul Steuperaert joined us as President, Cepheid Europe,SA in December 2002. Prior to joining Cepheid he was President, Europe & MEAA at Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories. Before joining Vysis, he held the position of President of Teleflex Medical SA and of Intermed SA, both medical devices companies. Mr. Steuperaert spent 20 years in various positions at American Hospital Supply Corporation ending as President of the Atlantic Division serving Europe and MEAA. Mr. Steuperaert is currently President of Cepheid HBDC, serving the compassionate sales of Cepheid products worldwide.